Glioblastoma is the most common malignant primary brain tumor. Overall, the prognosis for
patients with this disease is poor, with a median survival of< 2 years. There is a slight …

Glioblastoma multiforme (GBM) is the most common and aggressive malignant primary brain
tumour in humans and has a very poor prognosis. The existing treatments have had limited …

Activated EGFR signalling drives tumorigenicity in 50% of glioblastoma (GBM). However,
EGFR-targeting therapy has proven ineffective in treating patients with GBM, indicating that …

Glioblastoma (GBM) is the highest-grade form of glioma, as well as one of the most
aggressive types of cancer, exhibiting rapid cellular growth and highly invasive behavior …

Glioblastoma (WHO grade IV astrocytoma) is the most frequent primary brain tumor in adults,
representing a highly heterogeneous group of neoplasms that are among the most …

Glioblastoma multiforme (GBM) is a debilitating disease that is associated with poor
prognosis, short median patient survival and a very limited response to therapies. GBM has …

Temozolomide is the most widely used chemotherapy for patients with glioblastoma (GBM)
despite the fact that approximately half of treated patients have temozolomide resistance …

We have extended our understanding of the molecular biology that underlies adult
glioblastoma over many years. By contrast, high-grade gliomas in children and adolescents …

The DNA repair enzyme O 6-methylguanine-DNA methyltransferase (MGMT) antagonizes
the genotoxic effects of alkylating agents. MGMT promoter methylation is the key mechanism …

The epidermal growth factor receptor (EGFR) is overexpressed in a variety of human
epithelial tumors, often as a consequence of gene amplification. Tumors with EGFR gene …